Article Text

Download PDFPDF
Second-generation antidepressants and cognitive–behavioural therapy are both viable choices for initial treatment of major depression

Statistics from


  • Competing interests AN reports grants from Japanese Ministry of Health, Labour and Welfare, lecture fees from Eli Lilly, Pfizer, Mochida, Yoshitomi-Yakuhin, Otsuka, Dainippon Sumitomo, Tanabe-Mitsubishi and Meiji outside the submitted work.

  • Provenance and peer review Commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.